ST
ALXN

Smithfield Trust’s Alexion Pharmaceuticals ALXN Stock Holding History

Smithfield Trust’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-183
Closed -$34K – 1120
2021
Q2 		$34K Hold
183
– – ﹤0.01% 613
2021
Q1 		$28K Hold
183
– – ﹤0.01% 650
2020
Q4 		$29K Buy
183
+29
+19% +$3.73K ﹤0.01% 613
2020
Q3 		$17K Sell
154
-26
-14% -$2.81K ﹤0.01% 664
2020
Q2 		$20K Buy
+180
New +$19.1K ﹤0.01% 627
2018
Q1 		– Sell
-40
Closed -$5K – 1114
2017
Q4 		$5K Buy
+40
New +$4.87K ﹤0.01% 869

Other funds holding ALXN

BCI
Brinker Capital Investments Berwyn, Pennsylvania $13.1B AUM 28.37% 1-Year Est. Return
NICM
Neo Ivy Capital Management New York $434M AUM 44.19% 1-Year Est. Return
TAIM
TD Ameritrade Investment Management Omaha, Nebraska $9.4B AUM 7.2% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $521B AUM 51.41% 1-Year Est. Return
RG
Retirement Group San Diego, California $279M AUM 22.21% 1-Year Est. Return
CFO
CVA Family Office Denver, Colorado $1.1B AUM 26.6% 1-Year Est. Return
MAM
Meeder Asset Management Dublin, Ohio $1.96B AUM 48.96% 1-Year Est. Return

Smithfield Trust's ALXN Position: Q3 2021 in Review

Smithfield Trust sold out of Alexion Pharmaceuticals (ALXN) in Q3 2021, closing a stake of 183 shares — an estimated $34K sold.

Smithfield Trust first reported a position in ALXN in Q4 2017 and held it in 6 quarters. The position peaked at $34K in Q2 2021. 7 funds tracked by Wall St. Rank hold ALXN as of Q3 2021.

  • Smithfield Trust reported no remaining Alexion Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
  • Smithfield Trust sold 183 Alexion Pharmaceuticals shares in Q3 2021, an estimated $34K.
  • Smithfield Trust first reported a position in Alexion Pharmaceuticals in Q4 2017 and held it in 6 quarters.
  • Smithfield Trust's Alexion Pharmaceuticals position peaked at $34K in Q2 2021.
  • 7 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q3 2021.

Based on Smithfield Trust's 13F filing for Q3 2021, filed 12 Nov 2021.